Provided by Tiger Fintech (Singapore) Pte. Ltd.

BridgeBio Pharma, Inc.

31.37
-2.7000-7.92%
Post-market: 31.03-0.3400-1.08%17:35 EDT
Volume:4.02M
Turnover:128.35M
Market Cap:5.97B
PE:-10.90
High:33.89
Open:33.37
Low:30.86
Close:34.07
Loading ...

Company Profile

Company Name:
BridgeBio Pharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
728
Office Location:
3160 Porter Drive,Suite 250,Palo Alto,California,United States
Zip Code:
94304
Fax:
- -
Introduction:
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Directors

Name
Position
Charles Homcy
Chairman of Pharmaceuticals, Director
Frank McCormick
Chairman of Oncology
Neil Kumar
Chief Executive Officer, Director
Richard H. Scheller
Chairman of Research & Development, Director
Ali J. Satvat
Director
Eric Aguiar
Director
James C. Momtazee
Director

Shareholders

Name
Position
Neil Kumar
Chief Executive Officer, Director
Brian C. Stephenson
Chief Financial Officer
Cameron Turtle
Senior Vice President, Portfolio Management and Corporate Development
Michael Henderson
Senior Vice President, Asset Acquisition, Strategy and Operations
Uma Sinha
Chief Scientific Officer